List Results  
  Refine Search  
  Results by Topic  
  Results on Map  
  Search Details  
Found 87 studies with search of:   "Vaccinia"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Evaluation and Treatment of Eye Complications of Vaccinia Vaccination
Condition: Vaccinia
Intervention: Drug: NP-016 Vaccine Immune Globulin (IV-VIG)
2 Completed A Comparative Phase I Clinical Study of HIVAC-1e and Smallpox (Vaccinia) Vaccines in Previously (Vaccinia) Vaccinated and Unvaccinated Volunteers
Condition: HIV Infections
Interventions: Biological: Smallpox Vaccine;   Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
3 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
Condition: HIV Infections
Interventions: Biological: gp160 Vaccine (Immuno-AG);   Biological: rgp120/HIV-1IIIB;   Biological: rgp120/HIV-1MN;   Biological: rgp120/HIV-1 SF-2;   Biological: HIVAC-1e
4 Completed Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOT
Condition: Smallpox
Intervention: Biological: Wetvax (APSV)
5 Completed SIGA-246 to Treat Smallpox
Condition: Vaccinia
Intervention: Drug: Vaccine: SIGA-246
6 Terminated Vaccinia Immune Globulin in Treating or Preventing Vaccinal Infection
Conditions: Healthy;   Communicable Diseases
Intervention: Drug: Vaccinia Immune Globulin (Human)
7 Recruiting Safety Study of Vaccinia Virus to Treat Superficial Injectable Tumors
Conditions: Melanoma;   Breast Cancer;   Head and Neck Squamous Cell Cancer;   Hepatocellular Cancer;   Colorectal Cancer;   Pancreatic Adenocarcinoma
Interventions: Biological: Vaccinia virus (vvDD-CDSR);   Biological: Vaccinia virus (vvDD-CDSR)
8 Recruiting Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors
Conditions: Melanoma;   Lung Cancer;   Renal Cell Carcinoma;   Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
9 Completed Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
Condition: Smallpox
Intervention: Biological: ACAM3000 MVA Vaccine
10 Active, not recruiting Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
Condition: Melanoma
Interventions: Gene Transfer: Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes;   Biological: Intranodal booster immunizations with synthetic melanoma associated epitopes
11 Completed A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
12 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
13 Completed A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
Condition: Neoplasms, Liver
Intervention: Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
14 Completed A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
15 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated Schedules
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
16 Completed A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-Mcg Dose
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
17 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (Immuno-AG)
18 Completed Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against Smallpox
Condition: Healthy
Intervention: Drug: Modified Vaccinia Virus Ankara TBC-MVA
19 Completed A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines
Condition: HIV Infections
Interventions: Biological: rgp120/HIV-1 SF-2;   Biological: Env 2-3;   Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
20 Terminated Safety Study of MVA Smallpox Vaccine in HIV-Positive Subjects Who Are Vaccinia Naive
Conditions: HIV Infections;   Smallpox
Intervention: Biological: MVA Smallpox Vaccine

Previous Page Studies Shown (1-20) Next (21-40)
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services